Cargando…

Targeted Prostate Biopsy Using (68)Gallium PSMA-PET/CT for Image Guidance

Prostate specific membrane antigen (PSMA) scanning is a sensitive method of prostate cancer detection. In a 71 y.o. man with a PSA of 49 (6%F), 4 negative MRI studies and 6 negative biopsies over an 8 year interval, a (68)Ga-PSMA PET/CT scan showed a PSMA-avid spot in the prostate. Using image fusio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Simopoulos, Demetrios N., Natarajan, Shyam, Jones, Tonye A., Fendler, Wolfgang P., Sisk, Anthony E., Marks, Leonard S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2017
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5458645/ https://www.ncbi.nlm.nih.gov/pubmed/28607878 http://dx.doi.org/10.1016/j.eucr.2017.05.006

Ejemplares similares

Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer
por: Lenzo, Nat P., et al.
Publicado: (2018)

Clinical Utility of Gallium-68 PSMA PET/CT Scan for Prostate Cancer
por: Kallur, Kumaraswamy G, et al.
Publicado: (2017)

Diagnostic Impact of Dual-Time PET/CT with (68)Gallium-PSMA in Prostate Cancer and (68)Gallium-DOTATOC in Neuroendocrine Tumors
por: Librizzi, Damiano, et al.
Publicado: (2023)

Pitfalls in Gallium-68 PSMA PET/CT Interpretation—A Pictorial Review
por: Shetty, Deepa, et al.
Publicado: (2018)

Diagnostic performance of (68)Gallium-PSMA-11 PET/CT to detect significant prostate cancer and comparison with (18)FEC PET/CT
por: Hoffmann, Manuela A., et al.
Publicado: (2017)

(68)Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report
por: Rauscher, Isabel, et al.
Publicado: (2016)

Randomized prospective phase III trial of (68)Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]
por: Calais, Jeremie, et al.
Publicado: (2019)

The utility of gallium-68 DOTATOC PET/CT in lymphangioleiomyomatosis
por: Gaffney, Brian, et al.
Publicado: (2021)

Correction to: Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]
por: Calais, Jeremie, et al.
Publicado: (2019)

Repeatability of (68)Ga-PSMA-HBED-CC PET/CT–Derived Total Molecular Tumor Volume
por: Seifert, Robert, et al.
Publicado: (2022)

Staging Prostate Cancer with (68)Ga-PSMA-11 PET/CT in the Elderly: Is Preimaging Biopsy Imperative?
por: Kesler, Mikhail, et al.
Publicado: (2023)

Musculoskeletal pitfalls in (68)Ga-PSMA PET/CT
por: Pontes, Írline Cordeiro de Macedo, et al.
Publicado: (2023)

(68)Gallium-labelled PSMA-PET/CT as a diagnostic and clinical decision-making tool in Asian prostate cancer patients following prostatectomy
por: Tan, Janice S.H., et al.
Publicado: (2019)

The positivity rate of 68Gallium-PSMA-11 ligand PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer
por: Hoffmann, Manuela A., et al.
Publicado: (2019)

Pilot study: use of gallium-68 PSMA PET for detection of metastatic lesions in patients with renal tumour
por: Rhee, Handoo, et al.
Publicado: (2016)

The management impact of (68)gallium-tris(hydroxypyridinone) prostate-specific membrane antigen ((68)Ga-THP-PSMA) PET-CT imaging for high-risk and biochemically recurrent prostate cancer
por: Kulkarni, Meghana, et al.
Publicado: (2019)

Gallium-68 prostate-specific membrane antigen ([(68)Ga]Ga-PSMA-11) PET for imaging of thyroid cancer: a feasibility study
por: Lawhn-Heath, Courtney, et al.
Publicado: (2020)

Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225
por: Meyer, Catherine, et al.
Publicado: (2022)

Incidental detection of a tumour on 68-Gallium DOTANOC PET/CT
por: Shah, Hina J., et al.
Publicado: (2014)

Role of 68Ga-PSMA-PET/CT for the detection of primary prostate cancer prior to biopsy: a prospective study
por: Jain, Harsh, et al.
Publicado: (2021)

Specificity of (68)Ga-PSMA PET/CT for Prostate Cancer - Myths and Reality
por: Sasikumar, Arun
Publicado: (2017)

Meta-analysis of (18) F-PSMA-1007 PET/CT, (18) F-FDG PET/CT, and (68)Ga-PSMA PET/CT in diagnostic efficacy of prostate Cancer
por: Yu, Wenxiao, et al.
Publicado: (2023)

Direct comparison of (99m)Tc-PSMA SPECT/CT and (68)Ga-PSMA PET/CT in patients with prostate cancer
por: Albalooshi, Batool, et al.
Publicado: (2020)

Primary Staging of Prostate Cancer Patients with [(18)F]PSMA-1007 PET/CT Compared with [(68)Ga]Ga-PSMA-11 PET/CT
por: Hoffmann, Manuela A., et al.
Publicado: (2022)

Comparison of (68)Ga-PSMA PET/CT and (18)F-PSMA PET/CT of a Patient with Prostate Cancer Recurrence on Urinary Bladder Wall
por: Soydal, Çiğdem, et al.
Publicado: (2023)

Concomitant lung and gastroenteropancreatic neuroendocrine tumors and the value of gallium-68 PET/CT
por: Kaemmerer, Daniel, et al.
Publicado: (2011)

PET and PET/CT with (68)Gallium-Labeled Somatostatin Analogues in Non GEP-NETs Tumors
por: Sollini, Martina, et al.
Publicado: (2014)

(68)Ga-PSMA-PET/CT for the evaluation of liver metastases in patients with prostate cancer
por: Damjanovic, Jonathan, et al.
Publicado: (2019)

Re: The role of (68)Ga-PSMA-PET/CT in radiotherapy planning in prostate cancer
por: Cihan, Yasemin Benderli
Publicado: (2019)

Performance of Ga-68 PSMA PET/CT for diagnosis and grading of local prostate cancer
por: Kwan, Timothy N., et al.
Publicado: (2021)

Salvage lymph node dissection after (68)Ga-PSMA or (18)F-FEC PET/CT for nodal recurrence in prostate cancer patients
por: Herlemann, Annika, et al.
Publicado: (2017)

Comparison of (68)Ga-PSMA PET/CT with fluoride PET/CT for detection of bone metastatic disease in prostate cancer
por: Regula, Naresh, et al.
Publicado: (2022)

(68)Ga-PSMA PET-CT and PSMA score affecting therapeutic decision-making in high-risk prostatic carcinoma
por: Yasmin, Tahira, et al.
Publicado: (2023)

A VISION Substudy of Reader Agreement on (68)Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for (177)Lu-PSMA-617 Radioligand Therapy
por: Kuo, Phillip H., et al.
Publicado: (2023)

(68)Ga-PSMA-PET/CT and Diffusion MRI Targeting for Cone-Beam CT-Guided Bone Biopsies of Castration-Resistant Prostate Cancer Patients
por: van Steenbergen, T. R. F., et al.
Publicado: (2019)

Comparative gallium-68 labeling of TRAP-, NOTA-, and DOTA-peptides: practical consequences for the future of gallium-68-PET
por: Notni, Johannes, et al.
Publicado: (2012)

Splenosis Mimicking Relapse of a Neuroendocrine Tumor at Gallium-68-DOTATOC PET/CT
por: Treglia, Giorgio, et al.
Publicado: (2013)

SUN-314 Gallium-68 DOTATATE PET/CT for Preoperative Localization of Metastatic Insulinoma
por: Bratman, Russell, et al.
Publicado: (2019)

(68)Ga-PSMA PET-CT Imaging of Metastatic Adenoid Cystic Carcinoma
por: de Keizer, Bart, et al.
Publicado: (2016)

Time point-independent tumor positivity of (68)Ga-PSMA-PET/CT pre- and post-biopsy in high-risk prostate cancer
por: Zou, Sijuan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_llgoe6t588lv7j4livaabjkofb